Maura N. Dickler

Supplementary Fig. 4 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

Sarat Chandarlapaty, Maura N. Dickler, José Alejandro Pérez Fidalgo, Rafael Villanueva-Vázquez et autres

Supplementary Fig. S4. ESR1 mutation analysis in ctDNA.

Supplementary Fig. 2 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

Sarat Chandarlapaty, Maura N. Dickler, José Alejandro Pérez Fidalgo, Rafael Villanueva-Vázquez et autres

Supplementary Fig. S2. The PGR z-score for six patients analyzed in Fig. 4.

Supplementary Fig. 6 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

Sarat Chandarlapaty, Maura N. Dickler, José Alejandro Pérez Fidalgo, Rafael Villanueva-Vázquez et autres

Supplementary Fig. S6. Detection of short variant gene alterations using the FACT next generation sequencing assay on ctDNA samples from patients dosed at 1400 mg dose (n=23).

Supplementary Fig. 5 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

Sarat Chandarlapaty, Maura N. Dickler, José Alejandro Pérez Fidalgo, Rafael Villanueva-Vázquez et autres

Supplementary Fig. S5. Kaplan-Meier estimate of progression-free survival for patients with and without ESR1 mutations in baseline ctDNA samples collected from the 1400 mg dose group.ESR1 data was available for 36 of 36 patients dosed at 1400 mg.

Supplementary Fig. 1 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

Sarat Chandarlapaty, Maura N. Dickler, José Alejandro Pérez Fidalgo, Rafael Villanueva-Vázquez et autres

Supplementary Fig. S1. Study scheme.

Supplementary Fig. 3 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

Sarat Chandarlapaty, Maura N. Dickler, José Alejandro Pérez Fidalgo, Rafael Villanueva-Vázquez et autres

Supplementary Fig. S3. Clinical benefit does not correlate with ctDNA ESR1 mutant allele frequency (MAF) baseline levels or dynamics upon treatment, or with baseline ER and PR protein levels by IHC in tumor tissue.

Supplementary Data 1 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

Sarat Chandarlapaty, Maura N. Dickler, José Alejandro Pérez Fidalgo, Rafael Villanueva-Vázquez et autres

Supplementary Tables S1, S2, and S3.

Genome‐wide association studies of survival in 1520 cancer patients treated with bevacizumab‐containing regimens

Amy S. Etheridge, Hedy Lee Kindler, Maura N. Dickler, Monica M. Bertagnolli et autres

Germline variants might predict cancer progression. Bevacizumab improves overall survival (OS) in patients with advanced cancers. No biomarkers are available to identify patients that benefit from bevacizumab. A meta-analysis of genome-wide association studies (GWAS) was conducted in 1,520 patients from Phase III …

us (code pays fourni par la source)

Supplementary Table 1 from Advancing Global Health Equity in Oncology Clinical Trial Access

Tolulope Adewole, Björn Albrecht, Shaalan Beg, Otis Webb Brawley et autres

Supplementary Table 1: Authors and affiliations

Data from Advancing Global Health Equity in Oncology Clinical Trial Access

Tolulope Adewole, Björn Albrecht, Shaalan Beg, Otis Webb Brawley et autres

Summary: Despite exponentially increased industry investment in oncology research and development with more than $80 billion spent annually, patient enrollment in clinical trials remains below 5% globally. Our multistakeholder international cancer coalition envisions ecosystem transformation with capacity building through a global “hub-and-spoke” …

Supplementary Figure 2 from Advancing Global Health Equity in Oncology Clinical Trial Access

Tolulope Adewole, Björn Albrecht, Shaalan Beg, Otis Webb Brawley et autres

Supplementary Figure 2: Number of cancer cases and deaths across geography in 2020, Millions

Supplementary Figure 1 from Advancing Global Health Equity in Oncology Clinical Trial Access

Tolulope Adewole, Björn Albrecht, Shaalan Beg, Otis Webb Brawley et autres

Supplementary Figure 1: Number of cancer cases and deaths across indications in 2020, Millions